Purpose The purpose of this review is to clarify the role of botulinum toxin serotype A (BTX-
A) in the treatment of children with cerebral palsy (CP), with a special focus on the lower …

Objectives In the last 2 decades, BTX-A is increasingly being used in the management of
spasticity in children with Cerebral Palsy (CP) and there is no doubt about its effect on range …

Botulinum toxin A (BTX‐A) is increasingly being used in early management of spasticity in
ambulant children with cerebral palsy (CP), with the aim of improving function, promoting …

Management of children with cerebral palsy (CP) is the focus of considerable resources in
many countries, so that evaluation of the efficacy for new and established treatments is …

Botulinum toxin A is widely used for spasticity management in children with cerebral palsy,
although outcomes are unpredictable. The aim of this study was to identify criteria for …

During the past 25 years, botulinum toxin type A (BoNT-A) has become the most widely used
medical intervention in children with cerebral palsy. In this review we consider the gaps in …

CP is the most common cause of chronic disability in childhood occurring in 2–2.5/1000
births. It is a severe disorder and a significant number of patients present cognitive delay …

BACKGROUND. Spasticity is a prevalent disabling clinical symptom for children with
cerebral palsy. Treatment of spasticity with botulinum toxin in children with cerebral palsy …

Botulinum toxin A (BoNT-A) is considered a safe and effective therapy for children with
cerebral palsy (CP), especially in the hands of experienced injectors and for the majority of …

Spasticity, following the neurological disorder of cerebral palsy (CP), describes a
pathological condition, the central feature of which is involuntary and prolonged muscle …